Julie M. Bullock, PharmD

Senior Vice President, Drug Development Services
Certara, Integrated Drug Development

Dr. Bullock has over 20 years of drug development experience and is a recognized drug development scientist with scientific and regulatory expertise focused in the therapeutic areas of oncology/hematology and coagulation.

Accelerated Approval: Reality vs. Expectations
(Panel Discussion)
Tuesday, June 13, 2023
9:15 a.m. – 10:15 a.m. CT

VIEW AGENDA

Dr. Bullock is currently a Senior Vice President in the Integrated Drug Development (Consulting) Division of Certara. She has over 20 years of drug development experience and is a recognized drug development scientist with scientific and regulatory expertise focused in the therapeutic areas of oncology/hematology and coagulation. Julie has extensive experience in all development phases including regulatory interactions with major global health authorities (FDA, EMA, PMDA), due diligence, design of clinical development plans, pediatrics, dose-finding strategy and streamlining development for breakthrough therapies and accelerated approval. Julie is a Key Opinion Leader on the FDA’s Project Optimus (oncology dose finding) initiative and has provided risk-assessment and tactical dose justification support for over 80 early and late-stage oncology assets since the launch of Project Optimus in 2022.

In her current role, Dr. Bullock supports a global team of clinical pharmacologists, regulatory strategy and drug development scientists who provide program level and strategic support to Biotech and Pharma company portfolio programs.

Prior to her role at Certara Dr. Bullock was a Team Leader for the Hematology/Oncology review team in the Office of Clinical Pharmacology at the Center for Drug Evaluation and Research at the FDA. Julie’s FDA career spanned 10 years where she contributed to over 14 new molecular entity NDA/BLA filing applications, multiple supplemental NDA/BLA applications and countless IND related submissions submitted to the hematology/oncology division. Dr. Bullock received her Doctor of Pharmacy from Drake University and completed a drug development fellowship with the State University of New York at Buffalo and Novartis Pharmaceuticals.

Dr. Bullock received her Doctor of Pharmacy from Drake University and completed a drug development fellowship with the State University of New York at Buffalo and Novartis Pharmaceuticals.

EDUCATION

Learn more about our Crossroads 2023 Speakers!

Peter D’Alba

Aurelia Chaudhury

Edna Y. Marín Ramos

Sandy Kapur

Jenn McNary

ALL SPEAKERS

The South Carolina Pharmacy Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Continuing education credits will be available to participants who fully attend the program and then complete an online educational activity evaluation. A unique code given at each activity must be provided in the evaluation to receive credit. Grievances regarding the education program must be submitted in writing to the SCPhA ACPE Administrator immediately following the program.